Quarterly Report – Period to 30 June 2024

16 July 2024
Posted in Video
16 July 2024 Orthocell

Orthocell has today published its Quarterly Report for the period ended 30 June 2024.

Highlights for this Quarter:

  • Orthocell reports record quarterly revenue of $1.84 million and year-on-year growth of 30% to $6.72 million  
  • Strong balance sheet with $20.60 million cash at bank at the end of the quarter
  • OCC to launch third revenue generating product in SmrtGraft™ for tendon repair
  • Compelling 85% success rates from Remplir™ nerve repair study published in peer-reviewed clinical journal
  • Outstanding 98.6% success rate from Striate+™ dental implant post-market clinical study
  • Top-line results from Remplir™ US market authorisation study expected in Q4 CY24

Orthocell Managing Director, Paul Anderson, said:

“Orthocell has completed a record quarter with increasing revenues and strengthening the balance sheet. I am delighted with the performance of our distribution partners and the continued increase in product adoption. With a highly respected and experienced Board in place, we are in a strong position to continue to gain commercial traction and drive our innovative products into global markets.”

Click here to read today’s ASX release.